Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Among patients with COPD or fibrotic ILD, participation in a 3-week inpatient pulmonary rehabilitation program resulted in ...

The Alabama Chapter of the Cystic Fibrosis Foundation welcomes you! Volunteers are the key to our success and the lifeblood of our organization. We have many opportunities for you to get involved.